Massachusetts

Who we are

• February 24, 2025

  A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

• February 5, 2024

  ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)

• January 10, 2024

  Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

• January 9, 2024

  Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study

• January 8, 2024

  Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

• August 31, 2023

  A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

• July 24, 2023

  Fc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer

• February 7, 2023

  A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases

• December 1, 2022

  Phase 2 Study of DKN-01 in Colorectal Cancer

• July 26, 2022

  A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

12Next